Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

doi:10.1200/JCO.2015.64.2702

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2016

Scher Howard I, Morris Michael J, Stadler Walter M, Higano Celestia, Basch Ethan, Fizazi Karim, Antonarakis Emmanuel S, Beer Tomasz M, Carducci Michael A, Chi Kim N, Corn Paul G, de Bono Johann S, Dreicer Robert, George Daniel J, Heath Elisabeth I, Hussain Maha, Kelly Wm Kevin, Liu Glenn, Logothetis Christopher, Nanus David, Stein Mark N, Rathkopf Dana E, Slovin Susan F, Ryan Charles J, Sartor Oliver, Small Eric J, Smith Matthew Raymond, Sternberg Cora N, Taplin Mary-Ellen, Wilding George, Nelson Peter S, Schwartz Lawrence H, Halabi Susan, Kantoff Philip W, Armstrong Andrew J

Abstract excerpt

PURPOSE: Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups. METHODS: An international expert committee of prostate cancer clinical investigators (the Prostate Cancer Clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Consensus

Share to Diagnostic Imaging

Share to Drug Approval

Share to Kallikreins

Share to Molecular Diagnostic Techniques

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to Research Design

Source

Open in PubMed Open full text

Identifiers

PMID: 26903579
DOI: 10.1200/JCO.2015.64.2702
PMCID: PMC4872347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.PMID 26903579Read ↗

Clinical phenotypes of castration-resistant prostate cancer.Semantic proximity Read ↗

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate CancerSemantic proximity Read ↗

A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancerSemantic proximity Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerSemantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving towards a Personalized Treatment?Semantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?Semantic proximity Read ↗

[Metastatic castration-resistant prostate cancer-emerging trends in therapy].Semantic proximity Read ↗

Progress in the mechanism and drug development of castration-resistant prostate cancer.Semantic proximity Read ↗

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Semantic proximity Read ↗

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analysesSemantic proximity Read ↗

Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in EuropeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.